---
schema_version: "secwatch.filing_event.v1"
accession: "0001808805-25-000077"
form_type: "8-K"
ticker: "NAUT"
cik: "0001808805"
company_name: "Nautilus Biotechnology, Inc."
filed_at: "2025-10-28T23:59:59+00:00"
generated_at: "2026-05-17T01:58:22.378491+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Nautilus Biotechnology Q3 2025 net loss $13.6M; operating expenses down 19% to $15.5M

## Summary
- Net loss of $13.6M for Q3 2025, improved from $16.4M loss in Q3 2024.
- Operating expenses $15.5M, down 19% from $19.1M year-over-year.
- Cash and investments $168.5M as of Sept 30, 2025.
- Progress on Tau proteoform samples; early access program expected H1 2026; commercial launch late 2026.

## SEC filing metadata
- accession: 0001808805-25-000077
- form_type: 8-K
- ticker: NAUT
- cik: 0001808805
- company_name: Nautilus Biotechnology, Inc.
- filed_at: 2025-10-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808805/000180880525000077/0001808805-25-000077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808805/000180880525000077/naut-20251028.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001808805-25-000077
- JSON: https://secwatch.observer/filing/0001808805-25-000077.json
- Plain text: https://secwatch.observer/filing/0001808805-25-000077.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.